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Pantothenate kinase-associated neurodegeneration, caused by mutations in the PANK2 gene, is an autosomal recessive disorder
characterized by dystonia, dysarthria, rigidity, pigmentary retinal degeneration and brain iron accumulation. PANK2 encodes the
mitochondrial enzyme pantothenate kinase type 2, responsible for the phosphorylation of pantothenate or vitamin B5 in the
biosynthesis of co-enzyme A. A Pank2 knockout (Pank2/) mouse model did not recapitulate the human disease but showed
azoospermia and mitochondrial dysfunctions. We challenged this mouse model with a low glucose and high lipid content diet
(ketogenic diet) to stimulate lipid use by mitochondrial beta-oxidation. In the presence of a shortage of co-enzyme A, this diet
could evoke a general impairment of bioenergetic metabolism. Only Pank2/ mice fed with a ketogenic diet developed a
pantothenate kinase-associated neurodegeneration-like syndrome characterized by severe motor dysfunction, neurodegeneration
and severely altered mitochondria in the central and peripheral nervous systems. These mice also showed structural alteration of
muscle morphology, which was comparable with that observed in a patient with pantothenate kinase-associated neurodegen-
eration. We here demonstrate that pantethine administration can prevent the onset of the neuromuscular phenotype in mice
suggesting the possibility of experimental treatment in patients with pantothenate kinase-associated neurodegeneration.
Keywords: pantothenate kinase-associated neurodegeneration (PKAN); mitochondria; ketogenic diet; pantethine
Abbreviation: PKAN = pantothenate kinase-associated neurodegeneration
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Introduction
The common feature of a group of genetic disorders, termed
neurodegeneration with brain iron accumulation, is brain iron
overload identified by radiological and histopathological examin-
ations (Kruer et al., 2012). Different subtypes of neurodegenera-
tion with brain iron accumulation have been defined at the genetic
level but pantothenate kinase-associated neurodegeneration
(PKAN) syndrome is the most frequent form.
PKAN is caused by mutations in the PANK2 gene, which codes
for the mitochondrial enzyme pantothenate kinase 2. This enzyme
is involved in the co-enzyme A biosynthetic pathway, catalysing
the phosphorylation of vitamin B5 or pantothenate (Hayflick,
2003). PKAN usually manifests in childhood with gait disturbances
and rapidly progresses to a severe movement deficit with dystonia,
dysarthria and dysphagia. The hallmark of this disease is the eye-
of-the-tiger signal in the globus pallidus on T2-weighted MRI
(Hayflick et al., 2003; Gregory et al., 2009)
To date, the mechanistic connection linking PANK2 dysfunction,
neurodegeneration and alteration of iron homeostasis has not
been understood, thus preventing our comprehension of the
pathogenesis of the disease and the design of efficient therapeutic
strategies. It has been proposed that reduced PANK2 enzymatic
activity determines the accumulation of cysteine, which may che-
late iron thus promoting the formation of free radicals (Gregory
et al., 2008); alternatively, defects in co-enzyme A and, as a
consequence, in phospholipid metabolism may damage the mem-
branes and lead to increased oxidative stress, which may alter iron
homeostasis (Leonardi et al., 2007).
The mouse models of PKAN display incomplete phenotypes,
including hardly any brain iron accumulation. Pank2/ mice
show growth reduction, retinal degeneration, male infertility
because of azoospermia (Kuo et al., 2005), and mitochondrial
dysfunctions (Brunetti et al., 2012) under standard diet conditions.
Retinal degeneration (Kuo et al., 2005) was not confirmed in a
recent Pank2 knockout mouse (Garcia et al., 2012) and this
phenotype is uncertain. A movement disorder was present in
mice on a pantothenic acid-deficient diet (Kuo et al., 2007).
A Pank1 knockout mouse (Leonardi et al., 2010) displayed a
metabolic disorder characterized by altered fatty acid oxidation
and gluconeogenesis, causing mild hypoglycaemia. An additional
mouse model consisting of a double Pank1/Pank2 knockout
(Garcia et al., 2012) showed a severe phenotype characterized
by hypoglycaemia and hyperketonaemia leading to dysfunctional
post-natal development and premature death at 17 days.
Based on the role of co-enzyme A in several crucial cellular meta-
bolic pathways, we tested the hypothesis to stress the Pank2/
mouse model with a high-fat ketogenic diet. Ketone bodies pro-
duced by the ketogenic diet through fatty acid oxidation bypass
glycolysis and enter the citric acid cycle to produce oxidative phos-
phorylation (OXPHOS) substrate. Mice on a ketogenic diet use
mainly fatty acid oxidation and OXPHOS for ATP production as
compared to mice on a standard diet (Laffel, 1999). We observed
that only ketogenic diet-fed Pank2/ mice presented typical signs
of neurological and motor impairment, as well as neuropathological
findings, resembling the phenotype observed in patients with PKAN.
Moreover, these mice showed muscular dysfunctions with mito-
chondrial morphological alterations, which were also detected in
the muscle of a patient with PKAN.
Recently, a PANK2 knockout Drosophila model has shown that
panthethine can serve as a compound to bypass the block due to
severe impairment of pantothenate kinase and that it is able to res-
cue brain degeneration, mitochondrial dysfunction and locomotor
disabilities (Rana et al., 2010).
To determine if pantethine was able to counteract the disease
phenotype elicited in ketogenic diet-fed Pank2/ mice, we con-
tinuously administered pantethine in drinking water during the keto-
genic treatment. Our data indicated that pantethine treatment was
safe, with no side effects and was able to ameliorate both the ma-
jority of the symptoms in the nervous and muscular systems and the
morphological features of neuronal and mitochondrial damage.
Materials and methods
Animals and diets
Animal studies were approved by the Ethics Committee of the
Foundation IRCCS Neurological Institute C. Besta, in accordance
with guidelines of the Italian Ministry of Health: Project no. BT4/
2011. The use and care of animals followed the Italian Law D.L.
116/1992 and the EU directive 86/609/CEE.
Standard diet (Mucedola), ketogenic diet (E15149-30, ssniff
Spezialdiaten) and water were given ad libitum. Ketogenic diet compos-
ition: 79.2 % fat; 8% protein; 5% crude fibre; 4.5 % crude ash; 0.6%
starch; 0.7% sugar (31.6 MJ/kg), with multi-vitamin addition.
Pantethine (Sigma) was administered at a concentration of 15 mg/kg/
day in drinking water. The JM129/SvJ-C57BL/6 Pank2+ / mice used in
this study were kindly provided by Professor Hayflick (Kuo et al., 2005).
Animals were housed two or three in a cage, in a temperature-
controlled (21C) room with a 12 h light-dark cycle and 60% relative
humidity.
The experimental design included four groups of mice: (i) the
‘standard diet’ group composed of eight Pank2/ mice (four male
and four female) and nine Pank2+/+ (five male and four female) on a
standard diet for 2 months; (ii) the ‘standard diet + pantethine’ group
composed of eight Pank2/ mice (four male and four female) and 12
Pank2+ /+ (five male and seven female) on a standard diet with the
concomitant administration of pantethine for 2 months; (iii) the ‘keto-
genic diet’ group composed of 20 Pank2/ mice (nine male and 11
female) and 26 Pank2+ /+ (11 male and 15 female) on an ad libitum
ketogenic diet for 2 months; and (iv) the ‘ketogenic diet + pantethine’
group composed of 13 Pank2/ mice (five male and eight female)
and 16 Pank2+ /+ (five male and 11 female) on an ad libitum keto-
genic diet with the concomitant administration of pantethine.
Behavioural and motor skills analysis
The different groups were monitored weekly for onset of postural
abnormalities, loss of weight and general behavioural changes. We de-
tected spontaneous motor activity over a continuous period of 15 h (at
any time between 17:00 pm and 08:00 am) in an activity cage (Ugo
Basile) for four single-gender groups of 3-month-old Pank2+/+ and
Pank2/ mice, each comprising three mice of each genotype. In
total 12 Pank2+/+ and 12 Pank2/ mice were analysed.
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Measure of motor exercise endurance was evaluated using a tread-
mill apparatus (Columbus Instruments) counting the number of falls in
the motivational grid during a gradually accelerating program with
speed initially at 3.8 m/min and increasing by 3 m/min every 2 min.
The test was terminated by exhaustion, defined by 410 falls/min into
the motivational grid.
A footprint test was performed by painting hindlimbs with non-toxic
ink and placing mice at one end of an enclosed, dark tunnel on white
paper. Mice walked along a 28 cm long, 7 cm wide strip; stride length
and width of consecutive steps were measured. These tests were car-
ried out in 3-month-old mice to monitor the phenotype.
Histology, histochemistry and
immunohistochemistry
Histological, histochemical and immunohistochemical analyses were
performed on formalin-fixed and paraffin-embedded brain tissues
from the following treatment groups: standard diet Pank2+ /+
(n = 2); standard diet Pank2/ (n = 2); ketogenic diet Pank2+/+
(n = 4); ketogenic diet Pank2/ (n = 5); ketogenic diet + pantethine
Pank2+/+ (n = 3); ketogenic diet + pantethine Pank2/ (n = 3).
Briefly, whole formalin-fixed brains were cut in 2-mm thick slices
along the sagittal plane, and embedded in formalin. Five to 10-mm
thick serial sections were stained with haematoxylin-eosin, periodic
acid Schiff, Luxol fast blue and Perls’ stain. Immunohistochemistry
was performed using antibodies against amyloid precursor protein
(Abcam, 1:200), heavy molecular weight neurofilament (Abcam,
1:2000); ubiquitin (Dako, 1:50); phosphorylated tau (Abcam, 1:50),
alpha synuclein phospho specific (Covance, 1:200), NeuN (Millipore,
1:500), and glial fibrillary acidic protein (GFAP; Dako, 1:100).
Left quadricep skeletal muscle biopsies were performed in patients
according to a protocol approved by the Foundation IRCCS
Neurological Institute C. Besta. Morphological analysis in patient and
mouse skeletal muscle tissue was carried out on 8 mm cryostat sections
using standard histological and histochemical techniques (Dubowitz
et al. 1973). The reactions for COX and SDH were performed as
previously described (Sciacco and Bonilla, 1996). The following treat-
ment groups were analysed: standard diet Pank2+/+ (n = 2); standard
diet Pank2/ (n = 2); ketogenic diet Pank2+ /+ (n = 2); ketogenic
diet Pank2/ (n = 2); ketogenic diet + pantethine Pank2+ /+ (n = 2);
and ketogenic diet + pantethine Pank2/ (n = 2).
Evaluation of mitochondrial
bioenergetics
We analysed mitochondrial energy metabolism in isolated mitochon-
dria derived from brains of standard diet Pank2+/+ (n = 3); standard
diet Pank2/ (n = 3); standard diet + pantethine Pank2+/+ (n = 3);
and standard diet + pantethine Pank2/ (n = 3) mice, using an XF96
Extracellular Flux Analyzer (Seahorse Bioscience) as previously reported
(Brunetti et al., 2012).
Derivation of neurons from sciatic
nerve and analysis of mitochondrial
membrane potential
Detection of mitochondrial potential was performed using JC1 staining
kit on neurons derived from sciatic nerves isolated from adult mouse as
previously described (Brunetti et al., 2012).
Electron microscopy analysis
Sciatic nerve analysis was performed on the following treatment
groups: standard diet Pank2+/+ (n = 1); standard diet Pank2/
(n = 1); ketogenic diet Pank2+ /+ (n = 3); ketogenic diet Pank2/
(n = 3); ketogenic diet + pantethine Pank2+ /+ (n = 3); and ketogenic
diet + pantethine Pank2/ (n = 3). Sciatic nerves were surgically
removed and processed for epoxy resin embedding as previously
described (Brunetti et al., 2012). In particular, each sciatic nerve was
cut in proximal, middle and distal segments and dehydrated separately.
Ultrastructural analyses were conducted on each stump. Brain ultra-
structural analysis was performed on the following treatment groups:
standard diet Pank2+/+ (n = 1); standard diet Pank2/ (n = 1);
ketogenic diet Pank2+ /+ (n = 3); ketogenic diet Pank2/ (n = 3);
ketogenic diet + pantethine Pank2+ /+ (n = 3); and ketogenic diet +
pantethine Pank2/ (n = 3). Sagittally spliced brains were fixed by
immersion in glutaraldehyde (2.5% in phosphate buffer). After fix-
ation, serial sagittal slides of 1-mm thick were obtained. Selected
areas of interest were sampled, post-fixed in osmium tetroxide and
embedded in EponTM epoxy resin. Thin sections (80–90 nm) were
stained with uranyl acetate and lead citrate and examined with a
CM10 Philips electron microscope.
Patient and mouse muscle tissues were fixed in 2.5% glutaralde-
hyde, processed as previously described (Napoli et al., 2011) and
post-fixed in 2% osmium tetroxide for 1 h. After dehydration, the
specimens were embedded in epoxy resin. Ultrathin sections were
cut and stained with uranyl acetate and lead citrate, then examined
with a Zeiss electron microscope.
Results
Mice phenotyping
We constantly monitored the weight of Pank2+/+ and Pank2/
mice during the administration of standard or ketogenic diet. As
also previously reported (Kuo et al., 2005) Pank2/ mice under
standard diet showed a slight weight reduction as compared with
Pank2+/+ mice, whereas during ketogenic treatment Pank2/
mice showed a fast and progressive weight loss (Fig. 1A and B).
Moreover, only Pank2/ mice fed a ketogenic diet manifested
kyphosis with hunched position, (Fig. 1C), feet clasping (Fig. 1D),
whitening of the fur and rigidity of the tail (Fig. 1E), as well as
dystonic limb positioning (Fig. 1F).
We asked whether these signs could have been prevented by
pantethine administration. To this aim we treated a group of
Pank2+/+ and Pank2/ mice (‘ketogenic diet + pantethine’
group) with a ketogenic diet and the concomitant administration
of pantethine (15 mg/kg/day) in drinking water. This concentra-
tion was established based on a dosage of 900 mg/day in an adult
individual (n = 14) considering an average weight of 60 kg. We
also tested various concentrations of pantethine in mice over 3
weeks and determined that a dose of up to 480 mg/kg/day was
tolerated without any side effects on weight and drinking intake
(Supplementary Fig. 1).
We observed that, with pantethine administration to mice fed a
ketogenic diet, the weight of Pank2/ mice was similar to that of
Pank2+/+ mice (Fig. 1G), no signs of kyphosis or feet clasping were
present (Fig. 1H) and body size approached that of Pank2/ mice
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fed a standard diet (Fig. 1I). Most importantly, Pank2/ mice fed
a ketogenic diet died after 2 months whereas the administration of
pantethine prolonged their survival for up to 5 months (Fig. 1J). We
could not verify the recovery of retina degeneration as this initial
observation (Kuo et al., 2005) was not confirmed by our own in-
vestigations and also not reported in another Pank2 knockout
mouse model (Garcia et al., 2012). On the contrary, azoospermia
was confirmed in mice fed a standard diet and ketogenic diet but
was not rescued by pantethine treatment during the period of our
observation and with the dose used.
Motor performance evaluation
Pank2/ mice fed a ketogenic diet were lethargic and showed a
significant reduction of spontaneous movements as compared with
Pank2+ /+ mice fed a ketogenic diet, whereas no differences were
observed when fed a standard diet (Fig. 2A).
Quantitative motor tests revealed significantly lower activity in
Pank2/ mice on a ketogenic diet as compared with Pank2+ /+
mice; no differences were evident on a standard diet (Fig. 2B). The
footprint patterns were assessed quantitatively by measuring stride
length and hind base width. We found that Pank2/ mice on a
ketogenic diet exhibited shorter stride lengths and hind paw
width, and an irregular gait as compared with Pank2+ /+ mice
on a ketogenic diet (Fig. 2C). All of these abnormalities were re-
covered by pantethine treatment and Pank2/ mice behaved in
the same way as their control littermates (Fig. 2A–C).
Neuropathology of Pank2/ mice fed
a ketogenic diet
On histological and immunohistochemical analysis of the whole
brains we did not observe massive neural loss, gliosis or demye-
lination in Pank2/ mice on a standard diet or a ketogenic diet
(data not shown). However, we noticed the presence of small,
scattered groups of neurons with eosinophilic, periodic acid
Schiff-positive round cytoplasmic inclusions (Fig. 3A–C). These
features were observed only in Pank2/ mice on a ketogenic
diet, and were located mostly in the midbrain, putamen and
amygdala. On immunohistochemistry, the inclusions were sharply
positive for ubiquitin (Fig. 3D and F) and negative for amyloid
precursor protein, phosphorylated tau, -synuclein, and high mo-
lecular weight neurofilaments (not shown). In addition, ubiquitin
Figure 1 Mice phenotype. (A) Body weight of Pank2+/+ and Pank2/ mice fed a standard diet (SD). (B) Body weight of Pank2+/+
and Pank2/ mice on a ketogenic diet (KD). (C) Kyphosis with hunched position; (D) feet clasping in ketogenic diet-fed Pank2/
(arrow); (E) whitening of the fur and rigidity of the tail in ketogenic diet-fed Pank2/; (F) dystonic hindlimb position. (G) Body weight of
Pank2/ mice was similar to that of Pank2+/+ fed a ketogenic diet with pantethine administration (KD + P). (H) No sign of kyphosis or
feet clasping were present in Pank2/ mice on a ketogenic diet with pantethine administration (arrow). (I) Comparison of Pank2/
body size in mice on standard (SD), ketogenic (KD) and ketogenic + pantethine (KD + P) diets (J) Survival curves for different diet
conditions: Pank2/ mice fed a ketogenic diet died after 2 months (dotted green line); Pank2+/+ mice fed a ketogenic (dotted yellow
line); Pank2+/+ mice fed a ketogenic diet with pantethine (dotted pink line); Pank2/ mice fed a ketogenic diet with pantethine
administration prolonged their survival by up to 5 months (orange line); Pank2/ mice fed a standard diet (dotted brown line); and
Pank2+/+ mice fed a standard diet (blue line). In A, B and G, the red symbols indicate Pank2/; blue symbols indicate Pank2+/+ .
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stain highlighted finely granular cytoplasmic deposits in several
neurons, as well as large, ubiquitin positive degenerating neurons
(Fig. 3D and E). Iron deposits were not observed with Perl’s stain
(data not shown).
Pantethine treatment of Pank2/ mice on a ketogenic diet led
to the disappearance of neuronal cytoplasmic inclusion on haema-
toxylin-eosin and periodic acid Schiff stain. Ubiquitin was merely
detectable by immunohistochemistry after treatment (Fig. 3G) and
Figure 2 Motor performance evaluation. (A) Activity cage: no differences were observed in Pank2+/+ and Pank2/ mice on a standard
diet (SD) or with pantethine (SD + P); Pank2+/+mice were more active with pantethine treatment (*P50.05, two-tailed, unpaired
Student’s t-test). Pank2/ mice fed a ketogenic diet were lethargic and showed a significant reduction of spontaneous movements as
compared with Pank2+/+ mice on a ketogenic diet (**P50.001, two-tailed, unpaired Student’s t-test). Pantethine treatment (KD + P)
rescues the reduced movements. (B) Treadmill test: no differences in the distance travelled by Pank2+/+ and Pank2/ mice on a
standard diet (SD) or with pantethine (SD + P). Pank2/ mice on a ketogenic diet ran only 50 m as compared to 180 m of Pank2+ /+
mice (**P50.001, two-tailed, unpaired Student’s t-test). Pantethine treatment (KD + P) restored the running capability in Pank2/
mice and increased the performance in Pank2+/+ mice (*P50.05, two-tailed, unpaired Student’s t-test). (C) Footprint pattern:
Pank2/ mice fed a ketogenic diet showed shorter stride lengths and hind paw width, and an irregular gait as compared with Pank2+ /+
mice fed a ketogenic diet. Pantethine treatment (KD + P) abolishes the movement disorders. In A and B, the red bars indicate Pank2/
mice and blue bars indicate Pank2+ /+ mice, respectively.
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completely absent in ketogenic diet-Pank2+/+ mice brain
(Fig. 3H).
Ultrastructural features of central and
peripheral nervous systems
Ultrastructural analysis was performed on basal ganglia and periph-
eral nerve of Pank2/ and Pank2+/+ mice under different diet
conditions. In the basal ganglia, Pank2/ animals on a standard
diet showed the presence of numerous mitochondria with abnor-
mal, swollen cristae (Fig. 4). These features were worsened by a
ketogenic diet, which led to focal loss of cristae (Fig. 4). Pank2/
animals fed a ketogenic diet also showed cytoplasmic deposits of
lipofuscin (data not shown). Notably, pantethine administration
completely rescued the mitochondrial morphology of Pank2/ ani-
mals on a standard diet, which were indistinguishable from the
wild-type littermates (Fig. 4), and ameliorated the morphology of
ketogenic diet-fed Pank2/ mice (Fig. 4).
Ultrastructural analysis of peripheral nerve of Pank2/ animals
on a ketogenic diet showed the presence of swollen mitochondria,
characterized by cristae degeneration and by the presence of
amorphous material in the matrix (Fig. 5). Pantethine
Figure 3 Histology and immunohistochemistry of brains from Pank2/ mice fed a ketogenic diet and a ketogenic diet with pantethine.
The analysed animals were 3 months old. Round, eosinophilic, periodic acid Schiff-positive cytoplasmic inclusions were present in neurons
of Pank2/ mice fed a ketogenic diet (A–C, arrows in B and C). Cytoplasmic bodies are markedly positive on ubiquitin immunostain
(D and F, arrows). Scattered neurons showed a finely granular cytoplasmic stain for ubiquitin (D and E, asterisks). There were large
degenerating neurons with a diffuse positivity for ubiquitin (E, arrowhead). Ubiquitin stain was barely detected in neurons from Pank2/
mice fed a ketogenic diet with pantethine (G), which show histological and immunohistochemical features similar to their wild-type
littermates (H). Scale bars = 25 mm.
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administration was able to completely rescue the mitochondrial
morphology both in the PNS and CNS. No ultrastructural alter-
ations were observed in Pank2+/+ mice fed with standard or
ketogenic diets (Figs 4 and 5).
Pantethine restores mitochondrial
membrane potential of Pank2/
neurons
To evaluate mitochondrial membrane potential we used JC1
staining. As shown in Fig. 6, neurons derived from Pank2+ /+
animals treated with a standard or ketogenic diet presented red
fluorescent aggregates indicating the preservation of the mito-
chondrial membrane potential. On the contrary, neurons derived
from Pank2/ mice treated with a standard or ketogenic diet
presented with a diffuse green fluorescence (Fig. 6) confirming
the presence of a defective mitochondrial membrane potential.
Interestingly, neurons derived from Pank2/ mice under
Figure 5 Electron microscopy of peripheral nerve in Pank2+ /+
and Pank2/ mice under different diet conditions. The ana-
lysed animals were 3 months old. Sciatic nerve axons of
Pank2+ /+ mice on a standard diet (SD), standard diet + pan-
tethine (SD + P), ketogenic diet (KD) and ketogenic diet +
pantethine (KD + P) contain morphologically normal mito-
chondria. Sciatic nerve axons of Pank2/ mice on a standard
diet and ketogenic diet show swollen mitochondria with altered
cristae (arrows). Sciatic nerve axons of Pank2/ mice on a
standard diet + pantethine and ketogenic diet + pantethine
show a high prevalence of normally-shaped mitochondria
with regular cristae organization (arrowheads). Scale
bars = 500 mm.
Figure 4 Electron microscopy of basal ganglia in Pank2+ /+ and
Pank2/ mice under different diet conditions. The analysed
animals were 3 months old. Pank2+ /+ mice on a standard diet
(SD), a standard diet + pantethine (SD + P), ketogenic diet (KD)
and ketogenic diet + pantethine (KD + P) show normal mito-
chondria. Pank2/ mice on a standard diet show mitochondria
with swollen cristae (asterisks and insert). With a ketogenic diet
the mitochondrial morphology is worsened with focal loss of
cristae (arrow and insert). Pank2/ mice on standard diet with
pantethine were similar to wild-type littermates; with a keto-
genic diet with pantethine there is a prevalence of mitochondria
with normal cristae morphology, although a few mitochondria
still showed swollen cristae.
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standard and ketogenic treatment plus the addition of pantethine
in drinking water, showed predominantly red fluorescence aggre-
gates indicating that the mitochondrial membrane potential was
preserved.
Pantethine improves mitochondrial
respiration
We evaluated respiration with microscale oxygraphy on mitochon-
dria isolated from brains of Pank2+/+ and Pank2/ mice
treated with pantethine and we compared the results with
untreated mice. Measurement was not performed in mitochondria
derived from mice under ketogenic treatment because of tech-
nical difficulties, probably due to the presence of increased fat
levels in the brain. We measured basal oxygen consumption
rate, and oxygen consumption rate after ADP addition,
and after oligomycin addition. We observed that pantethine was
able to significantly increase oxygen consumption rate under all
conditions tested in both Pank2+/+ and Pank2/ mitochondria
(Fig. 7). In particular, pantethine determines a doubling in oxygen
consumption rate after ADP stimulation suggesting a tightly
coupled respiration with ATP production.
These differences were statistically significant as
demonstrated by an unpaired, two-sided Student’s t-test, assum-
ing unequal variance. Values for statistical significance were set at
P5 0.05.
Comparison of muscle derived from
Pank2/ mice on a ketogenic diet
versus a patient with pantothenate
kinase-associated neurodegeneration
COX histochemical reaction of the muscle derived from Pank2/
mice fed a ketogenic diet revealed a peculiar staining pattern, likely
because of the presence of abnormal mitochondria (Fig. 8A). We
had the opportunity to study the muscle biopsy of a 6-year-old
patient with PKAN (PANK2 mutations: N500I + IVS2-1G4A).
We did not observe any defects in the respiratory chain enzymatic
activities apart from a succinate dehydrogenase (SDH) activity
below the lower control value (not shown), but we found the
same COX staining pattern (Fig. 8B) observed in mice. To charac-
terize these mitochondria further we performed electron micros-
copy, which highlighted the presence of giant mitochondria
spanning the sarcomere between two neighbouring Z-lines and
showing irregularly shaped cristae (Fig. 8C).
The histological alterations of the Pank2/ muscle highlighted by
both trichrome and COX staining were absent in pantethine-treated
mice (Fig. 9). Moreover, no histological abnormalities were evident in
standard diet or ketogenic diet Pank2+/+ muscle (Fig. 9).
Plasma analysis
Plasma analysis showed an increase of cholesterol (Supplementary
Fig. 2A) and triglycerides (Supplementary Fig. 2B) in mice on a
Figure 6 Membrane potential in Pank2+ /+ and Pank2/ neurons derived from mice under different diet conditions. Neurons derived
from Pank2+ /+ animals treated with a standard (SD) or ketogenic diet (KD), with or without pantethine (P) presented red fluorescent
aggregates indicating the preservation of the mitochondrial membrane potential. Neurons derived from Pank2/ mice treated with a
standard or ketogenic diet presented with a diffuse green fluorescence confirming the presence of a defective mitochondrial membrane
potential. Neurons derived from Pank2/ mice with standard and ketogenic treatment plus the addition of pantethine, showed
predominantly red fluorescence aggregates, indicating preservation of mitochondrial membrane potential. Scale bars = 100 mm.
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ketogenic diet. As expected, pantethine was able to reduce the
levels of both (Supplementary Fig. 2A and B). A decrease of glu-
cose levels was detected in mice fed a ketogenic diet and a keto-
genic + pantethine diet (Supplementary Fig. 2C). Ketosis was
observed in mice fed a ketogenic diet and was maintained
during pantethine administration (Supplementary Fig. 2D).
Discussion
The Pank2/ mouse model did not recapitulate the clinical and
neuropathological features of the human condition (Kuo et al.,
2005; Brunetti et al., 2012). Based on the role of co-enzyme A
in several crucial metabolic pathways and considering the data
obtained by a metabolomics approach in patients with PKAN,
indicating the presence of impairment in lipid metabolism, we
tested the hypothesis to challenge this mouse model with a diet
containing high fat levels. Ketogenic diet consists of a low glucose
and high lipid content, stimulating lipid use by mitochondrial beta-
oxidation and ketone body production in the liver. Ketone bodies
are high-energy-content compounds that can be used as an
energy source by the brain, heart and skeletal muscle. We admin-
istered a low carbohydrate high-fat ketogenic diet to 2-month-old
Pank2/ and Pank2+ / + mice and evaluated the clinical and
biochemical phenotype.
We demonstrate here that the introduction of the ketogenic diet
resulted in the onset of a severe phenotype in Pank2/ mice
characterized by motor dysfunctions, neurological impairment
with feet-clasping, and exacerbated mitochondrial alterations,
which were also present in the brain and PNSs of 12-month-old
Pank2/ mice on a standard diet (Brunetti et al., 2012).
Moreover, this diet caused the premature death of Pank2/
mice.
Pank2/ mice fed a ketogenic diet did show the clinical signs
present in patients with PKAN, namely more severe movement
disorder and neurodegeneration. Importantly, these animals
showed histological and immunohistochemical features of neuro-
degeneration, with cytoplasmic accumulation of abnormal, ubiqui-
nated proteins as observed in the brains of patients with PKAN
(Kruer et al., 2011). However, the exact nature of the ubiquiti-
nated proteins in our model remains to be elucidated. As observed
in humans, cytoplasmic inclusions in Pank2/ mice were nega-
tive for -synuclein, confirming that PKAN neuropathological
findings are different from other forms of neurodegeneration
with brain iron accumulation.
We did not observe iron accumulation in Pank2/ mice on a
ketogenic diet, in contrast to that observed in human PKAN
brains. We cannot exclude that iron levels could be below the
detection level for the histological technique or that iron accumu-
lates over a period of time beyond our observation. These aspects
are still to be clarified and require further investigation.
The induction of a PKAN-like phenotype in Pank2/ mice fed
with a ketogenic diet, allowed us to have a model in which to test
therapeutic compounds. Recently, in the Drosophila dPANK/fbl
mutants it was shown that panthethine can work as a precursor
of co-enzyme A, even in the presence of severely reduced levels of
Figure 8 Muscle COX (cytochrome c oxidase) histochemical reaction and electron microscopy. (A) Pank2/ mice on a ketogenic diet.
(B) Patient with PKAN revealed the same peculiar staining pattern as mice fed a ketogenic diet. (C) Electron microscopy highlighted
the presence of giant mitochondria spanning the sarcomere between two neighbouring Z-lines and showing irregularly shaped cristae
(20 000).
Figure 7 Evaluation of mitochondrial bioenergetics status.
Oxygen consumption rate (OCR) in mitochondria isolated from
brains of Pank2+ /+ and Pank2/ mice treated with pantethine
and compared with untreated mice. We measured basal oxygen
consumption rate (OCR-B) after ADP addition (OCR-ADP), and
after oligomycin addition (OCR-O). Pantethine was able to
significantly increase oxygen consumption rate in both
Pank2+/+ and Pank2/ mitochondria, especially ADP-induced
respiration. Black, white and grey histograms indicate OCR-B, -
ADP, and -O, respectively. Bars indicate the standard deviation
(SD). **P50.01; *** P50.001 (unpaired, two-tail Student’s
t-test). WT = wild-type; KO = knock-out.
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functional pantothenate kinase and that it was able to rescue brain
degeneration, mitochondrial dysfunction and locomotor disabilities
(Rana et al., 2010). By reasoning on these data we decided to
administer pantethine to mice under ketogenic treatment and, as
an internal control, to mice on a standard diet. In Pank2/ mice
on a ketogenic diet, we observed the rescue of the clinical pheno-
type including the movement disorder, the amelioration of the
mitochondrial dysfunctions, and the extension of the lifespan as
previously demonstrated in Drosophila (Rana et al., 2010).
Treatment with pantethine dramatically improved both the histo-
logical features of neurodegeneration and the ultrastructural mito-
chondrial damage in Pank2/ mice fed a ketogenic diet. We did
not observe rescue of the azoospermic phenotype in mice. Fertility
was not thoroughly investigated in patients with PKAN because of
the severity of their clinical presentation and shortened lifespan.
However, analysis of sperm samples in two affected individuals
showed aberrant morphology and altered motility (Gregory and
Hayflick, 2005).
We also demonstrated that pantethine administration was able
to rescue the mitochondrial phenotype in neurons derived from
Pank2/ mice on a standard diet, indicating that its effectiveness
was not dependent on or influenced by the ketogenic treatment.
It is known that pantethine is rapidly converted into cysteamine
and pantothenate by the vanin enzyme, also known as pan-
tetheine hydrolase or pantetheinase (Kaskow et al., 2012).
Although pantethine is not able to cross the blood–brain barrier,
Bousquet et al. (2010) demonstrated that cysteamine can cross
the blood–brain barrier and in so doing can exert positive effects
on the striatum and substantia nigra (Gibrat and Cicchetti, 2011).
Cysteamine is able to enhance the expression of tyrosine hydro-
xylase protein and of the Nurr1 gene (now known as Nr4a2), and
to upregulate the expression of the Brain Derived Neurotrophic
Factor (BDNF). These neuroprotective effects of cysteamine and
of its dimer cystamine have been hypothesized to reflect the posi-
tive actions of this compound in Parkinson’s disease (Sun et al.,
2010; Gibrat and Cicchetti, 2011) and Huntington’s disease
(Borrell-Pages et al., 2006).
It has been observed that cysteamine and pantethine in drinking
water have beneficial effects in MPTP-induced mouse models of
Parkinson’s disease (Cornille et al., 2010; Sun et al., 2010) and
Figure 9 Gomori trichrome (TG) and COX histochemical reactions in muscle of Pank2+ /+ and Pank2/ mice under different diet
conditions. No alterations were present in Pank2+/+ mice. Ketogenic diet (KD) induced muscle histological abnormalities in Pank2/
mice (see also Fig. 8A) characterized by the presence of enlarged mitochondria. These alterations were rescued by pantethine adminis-
tration (KD + P). Magnification  400. SD = standard diet.
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would prevent neuronal degeneration in animal models of
Parkinson’s disease (Stack et al., 2008; Gibrat and Cicchetti,
2011). Moreover, in animal models of Huntington’s disease,
cysteamine exerts its neuroprotective effects by prolonging life-
span and decreasing motor symptoms (Dedeoglu et al., 2002;
Karpuj et al., 2002).
In agreement with these data, we can hypothesize that the
beneficial effects of pantethine in our model system were due to
its conversion into pantothenate and cysteamine. In fact, pan-
tethine is rapidly hydrolyzed to pantothenic acid and cysteamine
as it could not be detected in plasma after oral administration
(Wittwer et al., 1985). Cysteamine, the reduced form of cysta-
mine (2-aminoethanethiol) is approved by the FDA for the treat-
ment of cystinosis, a childhood disorder, which causes renal failure
through cystine intracellular accumulation (Dohil et al., 2010) and
in 2006 a small trial with this compound was initiated in patients
with Huntington’s disease (Dohil et al., 2010).
However, cysteamine causes side effects (Corden et al., 1981)
whereas pantethine has low toxicity (Knott et al., 1957; Schwartz
and Bagdon, 1964) and might act as a neutral systemic carrier that
would target cysteamine into the brain, avoiding toxicity and max-
imizing its efficacy.
The metabolism of cysteamine generates several intermediates
including hypotaurine and taurine. In addition to being the major
bile salt, in the form of taurocholate (Bouckenooghe et al., 2006),
taurine crosses the blood–brain barrier and is involved in brain
physiological activities such as inhibitory neurotransmission and
long-term potentiation (Muramatsu et al., 1978; Pasantes-
Morales et al., 1981). Recently, we observed a reduction of the
bile acids tauro and glycol cholate (Leoni et al., 2012) and an
alteration of lipid metabolism in plasma derived from patients
with PKAN, likely because of co-enzyme A shortage causing,
among others, dysfunctional fat assimilation.
Together with the data obtained in mice fed a high-fat diet,
these observations suggest that it is possible to trace a parallel
between patients with PKAN and Pank2/ mice under stressful
conditions. Moreover, it is important to consider that environmen-
tal factors, such as food intake, together with genetic background
could modulate the disease presentation by worsening or, on the
contrary, stabilizing the progression of the symptoms. This could
also explain the variability of the clinical presentation of the dis-
ease, with a spectrum of syndromes ranging from rapid to slowly
progressive.
Interestingly, we have analysed for the first time the muscle
histology of a genetically defined patient with PKAN. The first
neuromuscular examination was performed by Malandrini et al.
(1995) in two adult cases of clinically-defined Hallerworden-
Spatz disease, which showed the presence of subsarcolemmal
myeloid structures, features characteristic of inflammatory
myopathies.
In our study we demonstrated that the muscle of a 6-year-old
patient with PKAN showed giant mitochondria with a mild alter-
ation of the cristae and was histologically comparable with the
muscle of Pank2/ mice fed a ketogenic diet. These alterations
were rescued in mice after pantethine administration. This is a
relevant observation when considering the option of pantethine
administration to patients, as muscle analysis could represent the
quantitative read-out to evaluate the effect of the compound with
a minimal invasive procedure.
Taken together, these data strongly suggest that pantethine ad-
ministration to patients with PKAN should be considered as a pos-
sible, safe and non-toxic therapeutic approach. Moreover, our
data clearly demonstrate that an altered lipid metabolism, as a
result of co-enzyme A shortage, could represent one of the under-
lining causes of the disease. It is also possible, as demonstrated by
the presence of mitochondrial alteration in the mouse model and
in the muscle of a patient with PKAN, that mitochondria play a
relevant role or could be a concurrent cause in the pathogenic
mechanism of the disease. Interestingly, the presence of giant
mitochondria in muscle, although with slight morphological differ-
ences, resembles the picture present in another human disorder
caused by mutations in the CHKB gene and mainly characterized
by muscular dystrophy and mental retardation (Quinlivan et al.,
2013). CHKB encodes an enzyme catalysing the first step in de
novo phosphatidylcholine synthesis (Mitsuhashi et al., 2013).
CHKB and PANK2 are clearly part of different metabolic pathways
but they converge on phospholipid biosynthesis. It is tempting to
speculate that dysfunction of lipid metabolism is indeed the
common culprit of the generation of mitochondrial muscle alter-
ation observed in both disorders (Lamari et al., 2013).
We believe that the modulation of the diet composition in
Pank2 knockout mice has generated a useful model system in
which to test not only pantethine, but also additional compounds,
which could be beneficial for patients.
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